Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

The currently approved direct oral anticoagulants (DOACs) are increasingly used in clinical practice. Although serious bleeding risks are lower with DOACs than with vitamin K antagonists, bleeding remains the most frequent side effect. Andexanet alfa and idarucizumab are the currently approved speci...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2024-10, Vol.22 (10), p.2889-2899
Hauptverfasser:	Levy, Jerrold H., Shaw, Joseph R., Castellucci, Lana A., Connors, Jean M., Douketis, James, Lindhoff-Last, Edelgard, Rocca, Bianca, Samama, Charles Marc, Siegal, Deborah, Weitz, Jeffrey I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral andexanet Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Anticoagulants - administration & dosage Anticoagulants - adverse effects Anticoagulants - therapeutic use Arginine - analogs & derivatives bleeding Blood Coagulation - drug effects Dabigatran - administration & dosage Dabigatran - adverse effects direct oral anticoagulants Factor Xa - therapeutic use Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use factor XI inhibitors Hemorrhage - chemically induced Humans idarucizumab Piperazines prothrombin complex concentrates Recombinant Proteins - administration & dosage Recombinant Proteins - therapeutic use Risk Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!